Therapeutic Review Panel

The Therapeutic Review Panel (TRP) was an advisory body that was established to provide recommendations or advice based on the two therapeutic review pilot projects. The approach was evidence-based and the advice reflected current medical and scientific knowledge, as well as clinical practice in the Canadian health care system.

The TRP consisted of core and specialist expert members.

Members of the TRP abided by CADTH’s Conflict of Interest Guidelines and Code of Conduct. An honorarium was paid to members for their preparation and meeting time.

Dr. G. Michael Allan, MD, CCFP
Dr. Allan is an Associate Professor and Director of Evidence-Based Medicine in the Department of Family Medicine at the University of Alberta. He coordinates and teaches the evidence-based medicine curriculum in the family medicine residency program and the community health course. He is the Medical Director of the Toward Optimized Practice Program, which works to expand the depth and spread of evidence-based practice and quality of primary care in Alberta. In addition, Dr. Allan teaches at conferences, does research in Health Care Economics and Physician Education, and practises family medicine in a multi-disciplinary team setting. He also co-presents a weekly evidence-based educational podcast with the Therapeutics Education Collaboration. Conflict of Interest

Dr. Michael Allen, MD
Dr. Allen is Director, Special Projects and Associate Professor at Dalhousie University’s Continuing Medical Education program. Previous to beginning his current position in 1994, he worked as a family physician in rural and urban areas of Nova Scotia for 17 years. Dr. Allen has developed many educational interventions for rural and urban health professionals in Nova Scotia, including physicians, pharmacists and dentists. He helped start the Dalhousie Academic Detailing Service and was also instrumental in the formation of the Canadian Academic Detailing Collaboration. Dr. Allen has chaired and is a member of the Drug Evaluation Alliance of Nova Scotia. He is currently enrolled in a Masters Program in Community Health and Epidemiology to further develop his critical appraisal skills. Conflict of Interest

Dr. Bruce Carleton, BPharm, PharmD
Dr. Carleton is a Professor of Paediatrics and Pharmaceutical Sciences at the University of British Columbia (UBC). He is also the Director of the Pharmaceutical Outcomes Program, Children's and Women's Health Centre of BC, and Senior Clinician Scientist at the Child and Family Research Institute in Vancouver. Dr. Carleton's relevant experience in the area of drug policy implementation and evaluation includes work as a reviewer of clinical and pharmacoeconomic studies of drugs. He is experienced and skilled in the critical appraisal of drug therapies and has had considerable experience with practical issues around public plan formularies. He has served on both provincial and federal committees focused on drug effectiveness, drug safety, and drug policy development. Conflict of Interest

Dr. Ann Colbourne, MD, FRCPC, FACP
Dr. Colbourne is a Professor of Medicine as well as the Divisional Director of General Internal Medicine, Faculty of Medicine and Dentistry, and Vice-Chair (Clinical) for the Department of Medicine, Faculty of Medicine, at the University of Alberta. She is also Site Service Chief for Medicine at the University of Alberta Hospital site within Alberta Health Services. Her ambulatory clinical practice emphasizes diabetes care with an emphasis on health promotion and disease prevention. Dr. Colbourne currently leads a Telehealth initiative for insulin pump patients in Newfoundland, and she was the Newfoundland and Labrador physician lead for Chronic Disease Prevention and Management until summer 2008. Dr. Colbourne has had education and research roles with schools of pharmacy and nursing practitioners, and she also has extensive experience on committees, including pharmacy and therapeutics, ethics, and quality of care committees. Conflict of Interest

Dr. Doug Coyle, MA, MSc, PhD
Dr. Coyle is a Professor and the Director of Graduate Studies in the Department of Epidemiology and Community Medicine at the University of Ottawa. He is also a Senior Scientist at the Ottawa Hospital Research Institute and a former Research Fellow at the Centre for Health Economics, University of York, England. He has been a member of the Ontario Committee to Evaluate Drugs since 2006 and the Ontario Drugs for Rare Diseases Working Group since 2008. Conflict of Interest

Dr. Lisa Dolovich, BScPhm, PharmD, MSc, Chair, CERC
Dr. Lisa Dolovich is an academic pharmacist with a primary appointment as an Associate Professor in the Department of Family Medicine at McMaster University. She holds cross-appointments to the Departments of Medicine and Clinical Epidemiology and Biostatistics at McMaster and maintains a clinical practice in the Medication Assessment Clinic at St. Joseph’s Healthcare, Hamilton. Dr. Dolovich is a scientist at the Centre for Evaluation of Medicines (CEM), a multidisciplinary research group, whose aim is to promote the best use of drug and therapeutic interventions in the delivery of health care through research and educational activities. She leads a research program called the Team for Individualizing Pharmacotherapy in Primary Care for Seniors (TIPPS; www.tippsnetwork.ca) that aims to find better solutions to the problems seniors face when choosing or using medications in the primary care setting. TIPPS is one of the main research groups at CEM and in the Department of Family Medicine at McMaster. Dr. Dolovich has expertise in both qualitative and quantitative research methods, systematic overviews and meta-analyses as well as various areas related to health services interventions, educational interventions, drug use evaluation and pharmacy practice. Conflict of Interest

Dr. Stephanie Ensworth, BSc(Pharm), MD, FRCP, FRCPC(Rheum), ABIM
Dr. Ensworth is a Clinical Assistant Professor of Medicine, Division of Rheumatology at the University of British Columbia (UBC), where she has worked since 1990.
Dr. Ensworth is a rheumatologist at Vancouver Acute (the Vancouver General Hospital) and at Children's and Women's Health Centre of British Columbia. She is currently involved in multiple committees, some of which include: the Canadian Rheumatology Association (CRA); scientific and therapeutics committees; UBC Faculty of Medicine Executive; and the British Columbia Ministry of Health Services PharmaCare committee, as an initiating member since 2001, advising on the use of biologic agents in rheumatic diseases. In her career, Dr. Ensworth has been intimately involved in the development of and worked as an initiating director of several unique, multidisciplinary British Columbia provincial and Western Canadian clinics or programs, including the Young Adult Rheumatic Diseases Clinic and BC & Yukon Lupus Program at the Mary Pack Arthritis Centre; The Rheumatic Diseases in Pregnancy Program at BC Women’s Hospital; and The Recurrent Pregnancy Loss Clinic at BC’s Women’s Health Centre. She has taught, done research, and presented at national and international meetings on systemic lupus erythematosus, rheumatic diseases and their medications in pregnancy, as well as antiphospholipid syndrome in pregnancy. Conflict of Interest

Dr. Robyn Houlden, MD, FRCPC
Dr. Robyn Houlden is a Professor in the Faculty of Health Sciences at Queen's University in Kingston, a consultant in adult endocrinology at the Kingston General Hospital, and a medical advisor for the Diabetes Education and Management Centre at the Hotel Dieu Hospital in Kingston. She is actively involved in medical education at all levels and has been the recipient of numerous teaching awards. She is an investigator in a number of clinical trials of new therapies for diabetes and also has a research interest in innovative models of diabetes health care delivery. She played a steering role in the 2003 and 2008 Canadian Diabetes Association Clinical Practice Guidelines for the management of diabetes. In 2002, she was the recipient of the Charles Best Award from the Canadian Diabetes Association for her work in improving the quality of life for individuals with diabetes across Canada. Conflict of Interest

Dr. Jacob Karsh, MD, FRCPC
Dr. Karsh received his medical and rheumatology training at the Royal Victoria Hospital of McGill University, followed by three years of post-graduate training at the Arthritis Branch of the National Institutes of Health as an Arthritis Society Fellow and Fogarty Scholar. He is currently a professor of medicine at the University of Ottawa and a full-time hospital rheumatologist at the Ottawa Hospital. From 1992 until now, Dr. Karsh has been a consultant to Health Canada, serving as an external reviewer for nonsteroidal anti-inflammatory drugs and biologics. He has also been a consultant to the Canadian Agency for Drugs and Technologies in Health. Dr. Karsh is the former Co-Chairman of the infection and host defense block of the University of Ottawa undergraduate curriculum and a former Senior Editor of the Canadian Medical Association Journal. Conflict of Interest

Dr. Scott Klarenbach, MD, MSc, FRCPC
Dr. Scott Klarenbach is an Associate Professor in the Department of Medicine, Division of Nephrology at the University of Alberta in Edmonton; a Fellow at the Institute of Health Economics, and the Medical Director of Home Hemodialysis, Northern Alberta Renal Program. Dr. Klarenbach is a nephrologist and has an MSc in Health Economics from the University of York, in the United Kingdom. He has performed several economic evaluations, has been involved in several randomized trials, and collaborated on several systematic reviews. Dr. Klarenbach was involved in two full health technology assessments for CADTH, including the supervision of the economic evaluation, comparing continuous renal replacement therapy and intermittent hemodialysis as treatments for patients with acute renal failure in the ICU. Dr. Klarenbach was also undertaken pharmacoeconomic reviews for CADTH’s Common Drug Review. Conflict of Interest

Ms. Cathy MacNutt, BA, PMP
Mrs. MacNutt is a project manager involved in geriatric medicine research. She is a former Deputy Minister of Health for the province of Nova Scotia; Deputy National Director of Operations for Blood Services; and former Deputy Minister of Consumer Affairs in Nova Scotia. She has worked in public and private sector operations, including health services delivery, project management, corporate governance, strategic planning and organizational development. Mrs. MacNutt is serving on CERC as a public member, bringing a lay perspective to the proceedings. Conflict of Interest

Dr. Laurie Mallery, MD, FRCPC
Dr. Mallery is the Head of the Division of Geriatric Medicine at Dalhousie University and the Director of the Centre for Health Care of the Elderly at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. She is a Geriatrician and internist who is committed to evidence-based decision-making, with experience in drug evaluation. She was a member of the Nova Scotia Formulary Management Committee since 1993 and served as Chair since 2000. She chaired the Atlantic Common Drug Review Expert Advisory Committee since it was established in 2002 until 2009. Conflict of Interest

Mr. Brad Neubauer
Mr. Neubauer, a rancher and businessman in Irvine, Alberta, holds a Bachelor of Arts degree in Political Science and Philosophy. He has been actively involved as a member of the public in health care and has served as a member of local and provincial bioethics and research ethics committees. Mr. Neubauer has also volunteered his time and efforts in support of the local theatre community in Medicine Hat. Conflict of Interest

Dr. Lindsay Nicolle, MD, FRCPC
Dr. Nicolle is Professor of Internal Medicine and Medical Microbiology at the University of Manitoba and Consultant in Adult Infectious Diseases at the Health Sciences Centre and Winnipeg Regional Health Authority. She was Chair of the Department of Internal Medicine at the University of Manitoba from 1996 to 2001 where she has also previously served as a member and Chair of the Antimicrobial Review and Pharmacy and Therapeutics committees. During a sabbatical at the World Health Organization in 2001, Dr. Nicolle participated in the development of the Global Strategy for Antimicrobial Resistance. Conflict of Interest

Dr. Robert Peterson, MD, PhD, MPH
Dr. Peterson is a pediatrician, clinical pharmacologist, and medical toxicologist who is a Clinical Professor in the Department of Pediatrics, University of British Columbia, and Executive Director of the Drug Safety and Effectiveness Network, Canadian Institutes of Health Research. He is Chair of the Regulations Advisory Board of the Centre for Medicines Research International Institute for Regulatory Science. In this capacity, he participates actively in international drug development and regulation review and discussion. He was Director General of the Therapeutic Products Directorate at Health Canada for five years and led many innovations in drug regulatory policy during that time. Dr. Peterson has experience in clinical trials, been director of a research institute, and has participated in numerous international workshops on drug development. He completed a Master of Public Health degree in the area of Health Policy and Health Care Management and has a good appreciation of the evaluation and use of human prescription drugs. Dr. Peterson has been a member of Canadian Expert Drug Advisory Committee (CEDAC) since 2005. Conflict of Interest

Dr. Yvonne Shevchuk, B.S.P., Pharm D
Dr. Shevchuk is a Professor in the College of Pharmacy and Nutrition at the University of Saskatchewan where her areas of teaching focus in infectious diseases and research methods/evidence-based pharmacotherapy and drug information. Dr. Shevchuk is a long-time member of the Infectious Diseases Service at the Royal University Hospital and is involved in direct patient care. She has extensive committee experience, serving on both the Saskatchewan Formulary Committee and the Drug Quality Assessment Committee since 1991 and on the newly formed Drug Advisory Committee of Saskatchewan (DACS) since January 2010. In addition, Dr. Shevchuk is on the Board of the Saskatchewan Health Quality Council and the Advisory Board of RxFiles and is Director of the Saskatchewan Drug Information Service. Conflict of Interest

Dr. Jim Silvius, BA (Oxon), MD, FRCPC
Dr. Jim Silvius is an Associate Professor in the Department of Medicine, Division of Geriatric Medicine, at the University of Calgary. He obtained his BA in Physiology and Psychology from Oxford University, UK; his MD and Specialty in Internal Medicine from the University of Alberta; and his Specialty in Geriatric Medicine from Dalhousie University. He is currently the Senior Medical Director, Seniors' Health, Alberta Health Services, based in Calgary. He maintains a clinical practice in geriatrics at the Rockyview General Hospital. His primary research interests are in dementia care, though he also has an active interest in care delivery and led the development of the telehealth outreach program for the Department of Medicine at the University of Calgary until 2007. He is the current chair of the Alberta Medical Association’s Health Issues Council and is the Alberta representative to the Canadian Medical Association Committee on Health Care and Promotion. He has been a member of the Alberta Health and Wellness Expert Committee on Drug Evaluation and Therapeutics since 1999 and chair since 2004. He has also been a member of the Alberta Advisory Council on Health Technologies since May 2007. Conflict of Interest

Dr. Ehud Ur, MD, FRCP
Dr. Ur is a Professor of Medicine at the University of British Columbia (UBC) and Head of the UBC Division of Endocrinology at Vancouver Hospital and St. Paul’s Hospital in Vancouver, BC. A graduate of the University of London and trained in medicine and endocrinology, Dr. Ur came to Canada in 1992. Until 1997, he was Assistant Professor of Medicine at Memorial University in St. John’s, Newfoundland. Dr. Ur is Chair of the Canadian Diabetes Association (Clinical and Scientific Section) and was involved in the development of their national guidelines. He is also on the board of directors of Obesity Canada. Dr. Ur is actively engaged in both laboratory and clinical research in neuroendocrine disorders, diabetes, dyslipidemia, and obesity and was an investigator in clinical trials of a number of new agents. Conflict of Interest

Dr. Adil Virani, BSc Pharm, PharmD, FCSHP
Dr. Virani is a Director of Pharmacy Services with the Fraser Health Authority, Vancouver Coastal Health, Providence Health Care, and Provincial Health Services Authority, where he is responsible for the Professional Practice portfolio, Residency and Student Education, Academic Detailing, and pharmacy operations at Burnaby Hospital. He is an Associate Professor with the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC). He coordinates a therapeutics course for third-year pharmacy students and psychiatry residents in the Faculty of Medicine. He has published over 30 articles, has delivered over 100 presentations, and is the lead editor of the Clinical Handbook of Psychotropic Drugs, which is now in its 18th edition and is the 2009 American Journal of Nursing Book of the Year. He was also co-author of the Clinical Handbook of Psychotropic Drugs for Children and Adolescents (2nd edition). Dr. Virani is a member of the Education Working Group of the Therapeutics Initiative in BC, a member of the Human Drug Advisory Panel (HDAP) of the Patented Medicine Prices Review Board (PMPRB), and a Fellow of the Canadian Society of Hospital Pharmacists. Conflict of Interest

Conflict of Interests

Dr. Lisa Dolovich
Dr. Dolovich was co-investigator in studies on behaviour change interventions funded by Merck Frosst Canada Ltd., GlaxoSmithKline Inc., Sanofi-Aventis Pharma Inc., Eli Lilly Canada Inc. and Crystaal Corporation.

Dr. Robert Peterson
Dr. Peterson received unrestricted funding from Celgene Corporation to lecture on drug safety in China.

Dr. G. Michael Allan
Dr. Allan reports no conflict of interest in accordance with the Conflict of Interest Guidelines.

Dr. Michael Allen
Dr. Allen reports no conflict of interest in accordance with the Conflict of Interest Guidelines.

Dr. Bruce Carleton
Dr. Carleton has received research support for a national program to improve adverse drug reaction reporting and identification of genetic determinants of drug risk in children: “Canadian Pharmacogenomics Network for Drug Safety”. Funding has been provided by the Canadian Institutes of Health Research (CIHR) and Canada Foundation for Innovation (CFI) from January 2009 to 2013. The University of British Columbia has also received funds from Pfizer Canada that will be used as part of the grant provided by CIHR and CFI. Funding for the period 2004-2008 was primarily provided by Genome Canada with some support from Genome BC, Merck Frosst Canada, Pfizer Canada, Eli Lilly Canada and Janssen-Ortho that provide pooled funds matching government funds for this grant. The pharmaceutical industry has no formal or informal role in this program of research.

Dr. Doug Coyle
Dr. Coyle has received research funding from Eli Lilly Canada Inc., and compensation for consulting services from Bayer Inc. in 2008

Dr. Scott Klarenbach
Dr. Klarenbach is a member of a research group funded by an unrestricted grant from Amgen Canada and Merck Frosst Canada Ltd to the Alberta Kidney Disease Network

Mrs. Cathy MacNutt
Mrs. MacNutt reports no conflict of interest in accordance with the Conflict of Interest Guidelines.

Dr. Laurie Mallery
Dr. Mallery reports no conflict of interest in accordance with the Conflict of Interest Guidelines.

Mr. Brad Neubauer
Mr. Neubauer reports no conflict of interest in accordance with the Conflict of Interest Guidelines.

Dr. Lindsay Nicolle
Dr. Nicolle has received payment for consulting services from Pfizer US and Leo Pharma Inc.

Dr. Yvonne Shevchuk
Dr. Shevchuk has received financial support from Institut Rosell Inc. for work on probiotics.

Dr. Adil Virani
Dr. Virani reports no conflict of interest in accordance with the Conflict of Interest Guidelines.

Dr. Ann Colbourne
Dr. Colbourne has received honoraria for educational lectures for Novo Nordisk Canada Inc., Lifescan, Sanofi-Aventis Canada Inc., AstraZeneca Canada, Pfizer Canada Inc., and Merck Frosst Canada Ltd. of $5000 or less. She was involved in a community-based interprofessional collaborative chronic disease management program, funded by AstraZeneca Canada, Pfizer Canada Inc., and Merck Frosst Canada Ltd.

Dr. Stephanie Ensworth
Dr. Ensworth has received compensation for consulting or advisory services from GlaxoSmithKline Inc. in 2010.

Dr. Robyn Houlden
Dr. Houlden has received honoraria for educational lectures from Merck Frosst, Eli Lilly, AstraZeneca, Novo Nordisk, Sanofi-Aventis, Pfizer, and Boehringer Ingelheim. She has also received research grants from GlaxoSmithKline, Medtronic, Pfizer, AstraZeneca, and Eli Lilly.

Dr. Jacob Karsh
Dr. Karsh has received honoraria for educational lectures from Abbott Canada, Amgen Canada, Bristol-Myers Squibb Canada, Merck Frosst Canada Ltd., Pfizer, Roche Canada, Schering-Plough, and UCB Pharma Canada Inc. He has also received compensation for consulting or advisory services from Abbott Canada, Amgen Canada, Bristol-Myers Squibb Canada, Merck Frosst Canada Ltd., Pfizer, Roche Canada, Schering-Plough, and UCB Pharma Canada Inc.

Dr. Jim Silvius
Dr. Silvius reports no conflict of interest in accordance with the Conflict of Interest Guidelines.

Dr. Ehud Ur
Dr. Ur has received honoraria for educational lectures, honoraria for organizing conferences or other honoraria for $5000 or less from GlaxoSmithKline Inc., Novo Nordisk Canada Inc., Sanofi-Aventis Canada Inc., Merck Frosst Canada Ltd., and Novartis Pharmaceuticals Canada Inc. He has received funding for consultant or advisory services from GlaxoSmithKline Inc. and Novo Nordisk Canada Inc. and has received research grants through the Queen Elizabeth II Foundation (Halifax) from GlaxoSmithKline Inc., Novo Nordisk Canada Inc. and Lifescan.

Therapeutic Review Panel

Co-chairs

Core Members

Specialist Expert Members